DnaNudge, a London UK-based company focused on genetics testing and medical diagnostics, raised $60M in Series A funding.
The round was led by Ventura Capital with participation from Bank Julius Baer.
Led by co-fouder and CEO Chris Toumazou, DnaNudge leverages consumers’ own DNA plus lifestyle factors to nudge people towards healthier choices while shopping. The DnaNudge Nutrition service analyses and maps users’ genetic profile to key nutrition-related health traits such as obesity, diabetes, hypertension and cholesterol, enabling customers to be guided by their DNA towards healthier eating. The service has been developed by biomedical engineer Regius Professor Chris Toumazou FRS and published geneticist Dr Maria Karvela.
The company intends to use the funds to to accelerate the deployment of its rapid genetic testing solutions, including the sample-to-result RT-PCR COVID-19 test (‘CovidNudge’), which is in use in healthcare settings around the world.
DnaNudge is also providing CovidNudge testing as a private consumer service and is playing a key role in the safe return of the UK’s cultural sector. Arts organisations benefiting from DnaNudge’s regular pool testing of staff and performers include the Royal Opera House (home of the Royal Ballet), the London Symphony Orchestra and Glyndebourne opera house.
FinSMEs
31/08/2021